With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition

Verastem Oncology is now on the precipice of filing for an accelerated approval of a RAS pathway-based combo to treat low-grade serous ovarian cancer, and the transition follows a CEO turnover as Daniel Paterson, who has been with the company “almost since the beginning,” took the helm last year.